人型支原体、肺炎支原体和解脲脲原体对新型喹诺酮OPC 17116的敏感性
Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to a new quinolone, OPC 17116.
作者信息
Kenny G E, Cartwright F D
机构信息
Department of Pathobiology, University of Washington, Seattle 98195.
出版信息
Antimicrob Agents Chemother. 1993 Aug;37(8):1726-7. doi: 10.1128/AAC.37.8.1726.
Abstract
The susceptibilities of human mycoplasmas to OPC 17116 (Otsuka America Pharmaceutical, Inc., Rockville, Md.) and temafloxacin (Abbott Laboratories, Chicago, Ill.) were determined by the agar dilution method and were compared with those to sparfloxacin and ofloxacin. The MICs of OPC 17116 for 90% of Mycoplasma pneumoniae (0.25 microgram/ml) and Mycoplasma hominis (0.125 micrograms/ml) isolates tested were closely similar to those of sparfloxacin and were four- to eightfold greater than those of ofloxacin. Temafloxacin was two- to fourfold more active than ofloxacin. Ureaplasma urealyticum was less susceptible; the MICs of OPC 17116 and temafloxacin for 90% of isolates tested were 2 and 4.0 micrograms/ml, respectively.
摘要
采用琼脂稀释法测定了人型支原体对OPC 17116（大冢美国制药公司，马里兰州罗克维尔）和替马沙星（雅培实验室，伊利诺伊州芝加哥）的敏感性，并与它们对司帕沙星和氧氟沙星的敏感性进行了比较。OPC 17116对90%受试肺炎支原体（0.25微克/毫升）和人型支原体（0.125微克/毫升）分离株的最低抑菌浓度与司帕沙星的最低抑菌浓度非常相似，比氧氟沙星的最低抑菌浓度高4至8倍。替马沙星的活性比氧氟沙星高2至4倍。解脲脲原体的敏感性较低；OPC 17116和替马沙星对90%受试分离株的最低抑菌浓度分别为2微克/毫升和4.0微克/毫升。
相似文献
1
Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to a new quinolone, OPC 17116.人型支原体、肺炎支原体和解脲脲原体对新型喹诺酮OPC 17116的敏感性
Antimicrob Agents Chemother. 1993 Aug;37(8):1726-7. doi: 10.1128/AAC.37.8.1726.
2
Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219).肺炎支原体、人型支原体和解脲脲原体对新型喹诺酮类药物曲伐沙星（CP-99,219）的敏感性
Antimicrob Agents Chemother. 1996 Apr;40(4):1048-9. doi: 10.1128/AAC.40.4.1048.
3
Susceptibilities of Mycoplasma hominis and Ureaplasma urealyticum to two new quinolones, sparfloxacin and WIN 57273.人型支原体和解脲脲原体对两种新型喹诺酮类药物（司帕沙星和WIN 57273）的敏感性
Antimicrob Agents Chemother. 1991 Jul;35(7):1515-6. doi: 10.1128/AAC.35.7.1515.
4
[In vitro activity of sparfloxacin against mycoplasmas].
Pathol Biol (Paris). 1992 May;40(5):450-4.
5
In vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to sparfloxacin and PD 127391.肺炎支原体、人型支原体和解脲脲原体对司帕沙星和PD 127391的体外敏感性
Antimicrob Agents Chemother. 1991 Jun;35(6):1181-5. doi: 10.1128/AAC.35.6.1181.
6
In vitro antimycoplasmal activities of rufloxacin and its metabolite MF 922.芦氟沙星及其代谢物MF 922的体外抗支原体活性。
Antimicrob Agents Chemother. 1994 Nov;38(11):2651-4. doi: 10.1128/AAC.38.11.2651.
7
In vitro activity of sparfloxacin and other antimicrobial agents against genital pathogens.
Chemotherapy. 1992;38(5):303-7. doi: 10.1159/000239018.
8
In-vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum to clinafloxacin, PD 131628, ciprofloxacin and comparator drugs.肺炎支原体、人型支原体和解脲脲原体对克林沙星、PD 131628、环丙沙星及对照药物的体外敏感性。
J Antimicrob Chemother. 1997 Aug;40(2):308-9. doi: 10.1093/jac/40.2.308.
9
In-vitro activity of grepafloxacin, a new fluoroquinolone, against mycoplasmas.
J Antimicrob Chemother. 1999 May;43(5):711-4. doi: 10.1093/jac/43.5.711.
10
The in-vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum and Legionella spp.
J Antimicrob Chemother. 1997 Dec;40 Suppl A:31-4. doi: 10.1093/jac/40.suppl_1.31.
引用本文的文献
1
In vitro activity of a new quinoline derivative, ER-2, against clinical isolates of Mycoplasma pneumoniae and Mycoplasma hominis.新型喹啉衍生物ER-2对肺炎支原体和人型支原体临床分离株的体外活性
Antimicrob Agents Chemother. 2009 Dec;53(12):5317-8. doi: 10.1128/AAC.00746-09. Epub 2009 Sep 8.
2
Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia.在肺炎支原体肺炎小鼠模型中，替加环素治疗可显著降低肺部炎症细胞因子和趋化因子的浓度。
Antimicrob Agents Chemother. 2009 Apr;53(4):1546-51. doi: 10.1128/AAC.00979-08. Epub 2009 Jan 12.
3
In vitro susceptibilities of Mycoplasma hominis to six fluoroquinolones as determined by E test.采用E试验法测定人型支原体对六种氟喹诺酮类药物的体外敏感性。
Antimicrob Agents Chemother. 1999 Oct;43(10):2571-3. doi: 10.1128/AAC.43.10.2571.
4
Sparfloxacin selects gyrase mutations in first-step Mycoplasma hominis mutants, whereas ofloxacin selects topoisomerase IV mutations.司帕沙星在人型支原体第一步突变体中选择gyrase突变，而氧氟沙星选择拓扑异构酶IV突变。
Antimicrob Agents Chemother. 1999 Oct;43(10):2493-6. doi: 10.1128/AAC.43.10.2493.
5
Daily oral grepafloxacin vs. twice daily oral doxycycline in the treatment of Chlamydia trachomatis endocervical infection.每日口服格帕沙星与每日两次口服多西环素治疗沙眼衣原体宫颈感染的对比研究
Infect Dis Obstet Gynecol. 1998;6(3):109-15. doi: 10.1002/(SICI)1098-0997(1998)6:3<109::AID-IDOG3>3.0.CO;2-S.
6
In vitro activity of BAY 12-8039, a new fluoroquinolone against mycoplasmas.新型氟喹诺酮类药物BAY 12 - 8039对支原体的体外活性
Antimicrob Agents Chemother. 1998 Mar;42(3):703-4. doi: 10.1128/AAC.42.3.703.
7
Efficacy and safety of a 10-day course of 400 or 600 milligrams of grepafloxacin once daily for treatment of acute bacterial exacerbations of chronic bronchitis: comparison with a 10-day course of 500 milligrams of ciprofloxacin twice daily.每日一次服用400毫克或600毫克格帕沙星，疗程为10天，用于治疗慢性支气管炎急性细菌感染的疗效和安全性：与每日两次服用500毫克环丙沙星，疗程为10天进行比较。
Antimicrob Agents Chemother. 1998 Jan;42(1):114-20. doi: 10.1128/AAC.42.1.114.
8
Grepafloxacin.
Drugs. 1997 May;53(5):817-24; discussion 825-7. doi: 10.2165/00003495-199753050-00007.
9
Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219).肺炎支原体、人型支原体和解脲脲原体对新型喹诺酮类药物曲伐沙星（CP-99,219）的敏感性
Antimicrob Agents Chemother. 1996 Apr;40(4):1048-9. doi: 10.1128/AAC.40.4.1048.
10
In vitro activities of OPC-17116, a new quinolone; ofloxacin; and sparfloxacin against Chlamydia pneumoniae.新型喹诺酮类药物OPC - 17116、氧氟沙星及司帕沙星对肺炎衣原体的体外活性
Antimicrob Agents Chemother. 1994 Jun;38(6):1402-3. doi: 10.1128/AAC.38.6.1402.
本文引用的文献
1
Dissemination of the tetM tetracycline resistance determinant to Ureaplasma urealyticum.四环素抗性决定子tetM向解脲脲原体的传播。
Antimicrob Agents Chemother. 1986 Feb;29(2):350-2. doi: 10.1128/AAC.29.2.350.
2
Tetracycline-resistant Mycoplasma hominis strains contain streptococcal tetM sequences.耐四环素人型支原体菌株含有链球菌tetM序列。
Antimicrob Agents Chemother. 1985 Jul;28(1):141-3. doi: 10.1128/AAC.28.1.141.
3
In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolones.支原体和脲原体对新型大环内酯类药物及芳基氟喹诺酮类药物的体外敏感性
Antimicrob Agents Chemother. 1988 Oct;32(10):1500-2. doi: 10.1128/AAC.32.10.1500.
4
Susceptibilities of genital mycoplasmas to the newer quinolones as determined by the agar dilution method.采用琼脂稀释法测定生殖支原体对新型喹诺酮类药物的敏感性。
Antimicrob Agents Chemother. 1989 Jan;33(1):103-7. doi: 10.1128/AAC.33.1.103.
5
WIN 57273, a new fluoroquinolone with enhanced in vitro activity versus gram-positive pathogens.WIN 57273，一种对革兰氏阳性病原体具有增强体外活性的新型氟喹诺酮类药物。
Antimicrob Agents Chemother. 1990 Jul;34(7):1376-80. doi: 10.1128/AAC.34.7.1376.
6
Activity of temafloxacin against respiratory pathogens.替马沙星对呼吸道病原体的活性。
Antimicrob Agents Chemother. 1991 Mar;35(3):423-9. doi: 10.1128/AAC.35.3.423.
7
Fluoroquinolone antimicrobial agents.
N Engl J Med. 1991 Feb 7;324(6):384-94. doi: 10.1056/NEJM199102073240606.
8
Susceptibilities of Mycoplasma hominis and Ureaplasma urealyticum to two new quinolones, sparfloxacin and WIN 57273.人型支原体和解脲脲原体对两种新型喹诺酮类药物（司帕沙星和WIN 57273）的敏感性
Antimicrob Agents Chemother. 1991 Jul;35(7):1515-6. doi: 10.1128/AAC.35.7.1515.
9
Susceptibility of Mycoplasma pneumoniae to several new quinolones, tetracycline, and erythromycin.肺炎支原体对几种新型喹诺酮类、四环素类和红霉素的敏感性。
Antimicrob Agents Chemother. 1991 Mar;35(3):587-9. doi: 10.1128/AAC.35.3.587.
10
In vitro activity of sparfloxacin (CI-978, AT-4140, and PD 131501). A quinolone with high activity against gram-positive bacteria.司帕沙星（CI-978、AT-4140和PD 131501）的体外活性。一种对革兰氏阳性菌有高活性的喹诺酮类药物。
Diagn Microbiol Infect Dis. 1991 Sep-Oct;14(5):403-15. doi: 10.1016/0732-8893(91)90067-p.
Zotero 插件